Effects of the Revised Reimbursement Guideline for Anti-Osteoporosis Medication in South Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The Korean National Health Insurance (NHI) reimbursement guideline was revised in May 2015 with the aim of preventing secondary osteoporotic fractures. Here we compared the: (1) rate of bone mineral density (BMD) measurements; (2) prescrip- tion rate of anti-osteoporosis medication within 3 months after hip fracture surgery (HFS); (3) incidence of a second hip fracture; and (4) first-year mortality rate after HFS. Methods: This before-after study used the revised reimbursement system as a reference period. We retrospectively reviewed the medical records of 515 patients who underwent HFS at a tertiary referral hospital between January 2014 and December 2016. The period 1 group underwent HFS in 2014, while the period 2 group underwent HFS in 2016. Re- sults: Despite the fact that there was no significant intergroup difference in BMD mea- surement rate, the period 2 group had a higher prescription rate for anti-osteoporosis drugs within 3 months of HFS. However, the incidence of a second hip fracture did not differ between groups. The first-year mortality rate was higher in the period 1 versus pe- riod 2 group. Conclusions: Revision of the NHI guideline in May 2015 was associated with an increased prescription rate of anti-osteoporosis medication in osteoporotic hip fracture patients.
Abstract
Background: The Korean National Health Insurance (NHI) reimbursement guideline was revised in May 2015 with the aim of preventing secondary osteoporotic fractures. Here we compared the: (1) rate of bone mineral density (BMD) measurements; (2) prescrip- tion rate of anti-osteoporosis medication within 3 months after hip fracture surgery (HFS); (3) incidence of a second hip fracture; and (4) first-year mortality rate after HFS. Methods: This before-after study used the revised reimbursement system as a reference period. We retrospectively reviewed the medical records of 515 patients who underwent HFS at a tertiary referral hospital between January 2014 and December 2016. The period 1 group underwent HFS in 2014, while the period 2 group underwent HFS in 2016. Re- sults: Despite the fact that there was no significant intergroup difference in BMD mea- surement rate, the period 2 group had a higher prescription rate for anti-osteoporosis drugs within 3 months of HFS. However, the incidence of a second hip fracture did not differ between groups. The first-year mortality rate was higher in the period 1 versus pe- riod 2 group. Conclusions: Revision of the NHI guideline in May 2015 was associated with an increased prescription rate of anti-osteoporosis medication in osteoporotic hip fracture patients.
참고문헌 (19)
- 유제현, "Osteoporotic Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research", 대한골대사학회지, 22(4), pp.175~181 (2015), 대한골대사학회
- Delmas PD, "Treatment of postmenopausal osteoporosis", Lancet, 359, pp.2018~2026 (2002)[DOI]
- Reginster JY, "Osteoporosis : a still increasing prevalence", Bone, 38, pp.S4~S9 (2006)[DOI]
- Borgström F, "The societal burden of osteoporosis in Sweden", Bone, 40, pp.1602~1609 (2007)[DOI]
- Johnell O, "Epidemiology of osteoporotic fractures", Osteoporos Int, 16(Suppl 2), pp.S3~S7 (2005)[DOI]
- Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea", J Bone Miner Metab, 29, pp.744~751 (2011)[DOI]
- Brennan SL, "Examining the impact of reimbursement on referral to bone density testing for older adults: 8 years of data from the Barwon Statistical Division, Australia", Arch Osteoporos, 8, pp.152~ (2013)[DOI]
- Stuart AL, "Do reductions in out-of-pocket expenses for dual energy X-ray absorptiometry scans translate to reduced fracture incidence amongst older Australians? A population-based study", Arch Osteoporos, 13, pp.41~ (2018)[DOI]
- Jaglal S, "Impact of a change in physician reimbursement on bone mineral density testing in Ontario, Canada: a population-based study", CMAJ Open, 2, pp.E45~E50 (2014)[DOI]
- Koo JS, "Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older", PLoS One, 15, pp.e0244759~ (2020)[DOI]
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, "World Health Organization", 1~129, pp.World Health Organ Tech Rep Ser 843 (1994)
- Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)[DOI]
- Assessment of osteoporosis at the primary health care level. Summary report of a WHO scientific group, "World Health Organization", World Health Organization, ~ (2007)
- Omsland TK, "Mortality following the first hip fracture in Norwegian women and men (1999-2008). A NOREPOS study", Bone, 63, pp.81~86 (2014)[DOI]
- Panula J, "Mortality and cause of death in hip fracture patients aged 65 or older : a population-based study", BMC Musculoskelet Disord, 12, pp.105~ (2011)[DOI]
- Johnell O, "An estimate of the worldwide prevalence and disability associated with osteoporotic fractures", Osteoporos Int, 17, pp.1726~1733 (2006)[DOI]
- Lyles KW, "Zoledronic acid and clinical fractures and mortality after hip fracture", N Engl J Med, 357, pp.1799~1809 (2007)[DOI]
- Cengiz Ö, "Effects of zoledronate on mortality and morbidity after surgical treatment of hip fractures", Adv Orthop, 2016, pp.3703482~ (2016)[DOI]
- Beaupre LA, "Oral bisphosphonates are associated with reduced mortality after hip fracture", Osteoporos Int, 22, pp.983~991 (2011)[DOI]